11. July 2017
Transglutaminase-Newsletter | July 2017
ZediXclusive TG6-ab ELISA kits E103 and E104: Revised versions of ELISA kits E003 and E004.
Improvements:
Read more!
Get your serum sample measured for TG6 autoantibodies!
In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.
Link to Order Sheet (English)
Link to Order Sheet (German)
ELISA for detection of TG6 autoantibodies
Transglutaminase-Newsletter | July 2017
ZediXclusive TG6-ab ELISA kits E103 and E104: Revised versions of ELISA kits E003 and E004.
Improvements:
- Background subtraction not necessary anymore.
Therefore, now you can measure up to 40 sera in duplicates with one kit (96 wells). - The calibrators are adapted, so that the more relevant lower titers are covered.
Titers (U/mL) obtained by the new E103/E104 kits can be translated to titers of old kit versions E003/E004 and vice versa! - Cutoffs are redefined based on a sera collective of 86 patients with various neurological disorders, and 38 blood donors, equally distributed by sex and age.
Read more!
Get your serum sample measured for TG6 autoantibodies!
In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.
Link to Order Sheet (English)
Link to Order Sheet (German)
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation